31
1 | Page
1 | P a g e
2 | P a g e
Israel: A Powerhouse of Opportunities Over the last decade, Israel has introduced a wealth of
groundbreaking and valuable innovations in life sciences. Israel’s
life sciences sector is supported by a strong foundation of
academic excellence, including some of the world’s leading
research institutes, renowned R&D facilities and cutting-edge
medical centers. Bolstered by a highly skilled workforce, a
flourishing high-tech environment, and an entrepreneurial spirit,
Israeli companies have been joined by leading multinationals in
making Israel a recognized force in the industry worldwide. Global
giants, including Johnson & Johnson, Perrigo, GE Healthcare,
Phillips Medical, Abbott Laboratories, Merck Serono, Roche,
Takeda, Novartis, Monsanto , together with local companies such
as Teva - itself a multinational company - Given Imaging,
InSightec, Medinol and others have been continuously developing
and marketing life-changing medical breakthroughs and
innovations.
Prior to 1996, Israel was home to 186 life sciences companies. By
2014, this number had passed 1,300. With some 70 new
companies formed each year, 66 % of all life sciences companies
operating in Israel today were established during the last ten
years. In a relatively short period of time, an impressive 34% of
these companies have already begun to generate revenue,
demonstrating that Israel has crossed the threshold from an
attractive start-up arena to a source of advanced, commercially
viable and promising businesses. The bridge connecting excellent
science to revenue-generating companies has been established.
As proof of the industry’s development, in 2014 life sciences
exports reached $8.5 billion, an increase of 10% over 2010. A rich
pipeline of seed companies promises to perpetuate current
growth.
Source: Invest in Israel & IATI
Why Israel? Over 1000 life sciences
companies
Over 1/3 of LS Start-Ups already generate revenue
Source of numerous blockbuster drugs such as Copaxone and Rebif, generating over $5B in annual sales
First in the world in quality of scientific research institutions (World Economic Forum [WEF] 2011-12)
First in the world for medical device patents per capita, 2th for bio-pharma (US Patent Office 2011)
Pioneers in stem cell research and therapeutics
Extensive international R&D and commercial partnerships
World-renowned academic research institutes such as the Technion and the Weizmann Institute
Unique financing tools and incubator frameworks for start-ups
3 | P a g e
Israel’s Competitive Edge Academia and Research Approximately 50% of all academic research funding in Israel
is in the field of life sciences, and institutions such as the
Hebrew University of Jerusalem, Tel Aviv University, Ben
Gurion University of the Negev, the Technion-Israel Institute
of Technology and the Weizmann Institute of Science have
played dominant roles in advancing biotech R&D. In fact,
over the past five years, the Weizmann Institute was ranked
twice as the top international academic institution in the
world for scientists to conduct research in life sciences. In
2008, it was followed by the Hebrew University of Jerusalem
and in 2010, it was ranked second. This stems from
impressive levels of R&D funding and highly skilled and
creative manpower, which continues to generate new
patents in the field.
Cluster Effect Many of Israel’s achievements in the life sciences sector
stem from the fact that over 90% of the population resides
within two hours driving time of each other and within close
proximity to seven major universities and industrial clusters.
This cluster effect creates economies of scale, and allows for
better information sharing and synergies between the
companies.
Highly Educated and Highly Skilled
50% of the population aged 25-34 has attained at least
tertiary education, placing it sixth in the world behind
Singapore, Japan, and Korea (IMD Competitiveness Yearbook
2009). Approximately 24% of Israel’s workforce holds
university degrees - placing it third in the industrialized world
after the US and the Netherlands. Israel is ranked second in the
world in the percentage of engineers and scientists in the work
force (IMD 2009).
Entrepreneurial Spirit and Ingenuity
The exceptional volume of life science start-ups and patents attests to the entrepreneurial
and risk-taking climate in Israel. Israeli researchers and entrepreneurs overcome
technological barriers and solve development problems within a short period of time and at
a fraction of the cost of some of their larger and more affluent competitors overseas.
4 | P a g e
Rapid Research to Financial Return The last few years have witnessed several significant Israeli life sciences “exit” transactions with investors realizing impressive returns via IPOs, mergers and acquisitions. Close to 60 life science companies went public on the Tel Aviv Stock Exchange (TASE) in recent years, among them BiolineRx, Biondvax, Brainsway, Intec, Mazor, Prolor, Pluristem, Hadasit Bio Holdings and Nasvax, and approximately 15 Israeli companies have gone public on foreign exchanges, mainly in the US. According to the IVC Research Center, the value of M&As and IPOs in Israeli life sciences companies totaled $822 million in 2009.
Glance at Acquisitions of Israeli Life Sciences Companies 2008-2014
Company Acquirer Year Amount($M) Sector
Mediguide St Jude 2008 300 Medical Device
Omrix J&J 2008 438 Biotechnology
Ventor Medtronic 2009 325 Medical Device
Optonol Alcon 2009 160 Medical Device
Starlims Abbott 2009 123 Health IT
Medingo Roche 2010 160 Medical Device
Shamir Optical Essilor International 2010 260 Medical Device
Taro Sun Pharmaceutical 2010 117 Biotechnology
Beeologics Monsanto 2011 75 Agrobiotech
SuperDimension Covidien 2012 300 Medical Device
Oridion Covidien 2012 346 Medical Device
Polytouch Covidien 2012 356 Medical Device
Surpass Medical Stryker Corp. 2012 135 Medical Device
dbMotion Allscript 2013 235 Health IT
Given Imaging Covidien 2013 970 Medical Device
Alma Lasers Fosum Pharma 2013 240 Medical Device
Prolor OPKO Healthcare 2013 480 Biotechnology
Caesarea Medical Electronics CareFusion 2013 250 Medical Device
Angioscore Spectrnetics 2014 230 Medical Device
Simbionix 3D Systems 2014 120 Health IT
ColoRight Loreal 2014 175 Medical Device
Source: Invest in Israel
5 | P a g e
Meet the Sponsoring Organizations
The sponsoring organizations of the Israeli delegation provide a full array of support and
services to nurture the development of industry and innovation:
The Office of the Chief Scientist (OCS) is responsible for the
encouragement of industrial R&D. The OCS annually grants financial
support to hundreds of projects spanning from incipient concepts
within a pre-seed framework, through seed stage companies in
incubators, to start- up companies and R&D projects of revenue
generating enterprises. In the international arena, the OCS is vigorously
pursuing several avenues of industrial R&D collaboration between
Israeli companies and foreign companies, both through governmental
and global corporate agreements. The OCS grants preferential support
to life sciences companies and recently launched a government backed
life sciences VC Fund – a joint venture between the government and
international private sector.
MATIMOP is Israel’s national agency for international cooperation in
industrial R&D. MATIMOP implements the international R&D policy of
the Office of the Chief Scientist (OCS), facilitating joint ventures and
providing access to funding. MATIMOP is sponsoring the construction of
the Israeli Pavilion at the BIO Convention.
The Israel Advanced Technology Industries (IATI) is Israel’s largest
umbrella organization for companies, organizations, and individuals in
the high tech and life science sectors. In a country like Israel where
innovation is a national mindset, IATI’s mission is to strengthen the
Israeli high tech and life science industries across the whole value chain
and create global, technological and innovational leadership.
The US-Israel Science and Technology Foundation supports programs to
create a seamless infrastructure for industry, academia and government
for the mutual benefit for the economies of the US and Israel.
6 | P a g e
The Foreign Trade Administration at the Ministry of Economy is
responsible for managing and directing the international trade policy of
the State of Israel. The main fields of activity include activities for the
promotion of trade and export, initiating and maintaining trade
agreements for the improvement of Israel’s trade conditions, attracting
and encouraging foreign investments and creating strategic cooperation
with foreign companies.
The Enterprise Europe Network (EEN) is made up of over 600 partner
organizations in more than 50 countries, promoting competitive and
innovative international cooperation. EEN Israel consists of three
Israeli partners: ISERD-MATIMOP – EEN Israel's coordinator which is
also in charge of R&D issues (Uri Fishelson - [email protected]);
Manufacturers Association of Israel (MAI) in charge of technology
transfer (Sima Amir [email protected]) and The Israel Export and
International Cooperation Institute (IEICI) in charge of commercial
cooperation (Gil Oren [email protected]).
Meet the 2015 Bio Israeli Delegation
On behalf of the organizers and partners, we would like to introduce you to the 2015 Bio
Israeli Delegation. Twenty remarkable companies are attending, spanning the spectrum of
Israel’s vigorous life science community, from innovative start-ups to established companies.
Please take the time to explore their innovative solutions which you can find in this catalog.
We hope you will take the time to schedule a meeting with some of these companies and
see for yourself why Israel is driving innovation in the life sciences industry. You can visit the
Israel national pavilion at Booth 427
Additionally, most of the Israeli companies are participating in the Bio Business Forum
one-on-one partnering service, and you can find them in the online system at:
http://convention.bio.org/partner/
7 | P a g e
Israeli Company Profiles
Company Name Page
Biocep 10
BiondVax Pharmaceuticals Ltd.
11
BioRap Technologies 12
BMR Solutions 13
BrainStorm Cell Therapeutics
14
Brainsway Ltd 15
Can-Fite BioPharma Ltd. 16
Compugen Ltd. 17
DALI Medical Devices 18
8 | P a g e
Foamix Pharmaceuticals 19
Immune
Pharmaceuticals 20
Immune System Key 21
KAHR Medical Ltd. 22
NovellusDx 23
Oramed 24
Raziel Therapeutics 25
PolyPid 26
Sheltagen Medical Ltd 27
VBL Therapeutics 28
XTL Biopharmaceuticals 29
9 | P a g e
Company Profile:
BioCEP was established in 2006 as part of the
Israeli Office of Chief Scientist’s incubator
program. Today the company maintains a
corporate office and R&D center in Yokneam,
Israel and clinical research facilities out of the
Seiff Medical Center in Israel. BioCEP’s team
includes scientists, bioengineers, engineers and
management.
BioCEP’s technology is an advanced method in
cell separation with rare cell isolation and single
cell suspension collection abilities. Patented in
17 countries, the CEP isolates cells with high
recovery and purity rates, boasting 99% viability
of the isolated cells. These advantages enable
the development of novel diagnostic and therapeutic applications in markets with huge
potential. BioCEP is currently completing improvements on its R&D device, the CEPir, and
has sold research use devices to research partners in the US, Europe, and Asia, and has
begun establishment of distributor network towards market penetration in Q2 2015.
The Technology:
BioCEP has developed an improved method for cell separation, the CEP (Cell Enrichment
Process). CEP's results far surpass those of state-of-the-art systems allowing effective
separation of even rare cell populations of 1 in 109, such as fetal cells from the maternal
blood stream or circulating tumor cells (CTCs). Additional advantages of the CEP include fast
separation in a flow through fashion, a non-hostile separation environment which ensures
cell viability of 99%, and a circular separation option for increased effectiveness. The CEPir
includes optimized protocols for various cell populations and is installed at a handful of
academic and commercial sites in cutting edge fields such as CTC isolation and stem cell
therapies. Prenatal Diagnosis - BioCEP’s first application - is an early, non-invasive, diagnostic
test for the prenatal market. The CEP enables effective separation of rare fetal cells from
the maternal blood stream. These cells can be genetically analyzed by genetic labs,
replacing the invasive and potentially harmful CVS and amniocentesis tests performed today
as well as the non-conclusive screening tests. The company has completed a proof-of-
concept and has already performed over 20 consecutive successful cases of Fetal Cells
isolation. BioCEP will partner with genetic laboratories that offer prenatal screening or
diagnostic tests, reagent developers, and diagnostic companies. Discussions with a number
of potential partners are underway.
Company Name: BioCEP Ltd
Contact Details
Address: 13 Hayetzira, Yokneam, Israel
Phone: +972-4-86-86-900
Fax: +972-4-86-86-901
Email: [email protected]
Website: www.biocep.com
Exhibition Representatives
Name: Hannoch Marksheid
E-mail: [email protected]
Category: Medical Instrumentation,
Diagnostics
10 | P a g e
Company Name: BiondVax
Pharmaceuticals Ltd.
Contact Details
Address: Science Park, 14 Einstein St. PO
Box 4143, Ness Ziona, 7414002, Israel
Phone: +972-8-9302529 Fax: +972-8-9302531 Email: [email protected] Website: www.Biondvax.com
Exhibition Representatives Name: Ron Babecoff, CEO, Limor Chen, BD
Category: Vaccines
Company Profile:
BiondVax Pharmaceuticals Ltd. is an innovative
biopharmaceutical company developing a
Universal Flu Vaccine, designed to provide multi-
season and multi-strain protection against
human influenza virus, seasonal and pandemic,
existing or future strains. BiondVax has executed
a worldwide, exclusive license agreement with
Yeda (the commercial arm of the Weizmann
Institute of Science) for developing,
manufacturing and exploiting this innovative
influenza vaccine. The BiondVax’ technology
utilizes a unique, proprietary combination of
conserved and common epitopes of influenza
virus proteins to activate both arms of the
immune system for a cross-protecting and long-
lasting effect. The Universal Flu Vaccine is the product of an intensive research and
development effort conducted by Professor Ruth Arnon and her team at the Weizmann
Institute. Prof. Arnon is known for co-developing Copaxone®, the billion dollar drug for
Multiple Sclerosis commercialized by Teva Pharmaceuticals. BiondVax is an advanced phase
2 clinical stage company. We have successfully completed four trials with 440 young adults
to elderly participants, and two studies, in Israel and Europe, are now ongoing. In all trials
the vaccine was shown to be safe and immunogenic showing superior efficacy over existing
flu vaccines when given as a primer.
Technology Description:
The general concept of the company's scientific approach is to use a combination of
conserved epitopes derived from the influenza virus proteins that are devised into a single
recombinant protein. The epitope based approach taken by the Company's vaccine
overcomes common drawbacks in currently available vaccines, e.g., frequent mismatch to
circulating strains, long production cycle and allergy caused by egg products. These
limitations are overcome as the recombinant protein induces broad strain immunity and is
produced in bacteria, hence requiring a significantly shorter production cycle (6-8 weeks
instead of about 6 months). Additionally, such a recombinant protein is not causing allergic
reactions to hen eggs.
11 | P a g e
Company Profile:
BioRap Technologies, the technology transfer
company of the Rappaport Family Institute for
Research in the Medical Sciences, was
established to manage the commercialization of
intellectual property developed by its members.
The Rappaport Institute counts two Nobel Prize
Laureates among its members. Azilect, a drug
for Parkinson's disease, developed and marketed
by Teva, was invented by a Rappaport Institute
principal investigator. The Rappaport Institute is
affiliated with the Faculty of Medicine of the
Technion-Israel Institute of Technology.
BioRap provides Rappaport Institute
investigators with assistance in business
development, strategic alliance development,
identification of investors, establishment of startups, and other areas associated with
commercialization of biomedical discoveries and technologies. BioRap offers investors and
potential strategic partners a diverse portfolio of opportunities representing the most up-to-
date life science technologies.
Technology Description:
BioRap Technologies specializes in life science and its portfolio is composed of novel
biopharmaceuticals, vaccines and diagnostic projects. All the projects, ready for licensing
and/or collaboration, are in advanced pre-clinical stage with extensive in-vitro and in-vivo
proof of concept. Biorap Technologies operates in the fields of oncology, autoimmunity,
CNS, cardiology, nephrology and infectious diseases.
Company Name: Biorap Technologies
Contact Details
Address: 1 Efron St, POBox 2360, Haifa,
Israel
Phone: +972-4-8295402
Fax: +972-4-8524756
Email: [email protected]
Website: www.bio-rap.com
Exhibition Representatives
Name: Dr Orit Shaked
E-mail: [email protected]
Category: Biopharmaceuticals,
diagnostics and vaccines
12 | P a g e
Company Profile:
BMR Solutions is a privately held Israeli
biopharmaceutical startup company with a
pipeline of small molecule drugs in late pre-
clinical stages, addressing age related diseases
and cancer supportive care in elderly patients.
Based on the proprietary discovery of the
BMRH platform, we do endogenous stimulation
of adult stem cells. Our objective is to develop
and commercialize BMRH stem cells
modulators, for improvement of self-
regenerative capacity of the body.
Technology Description:
Our drugs were discovered in animal source as
a part of four decades of research aimed at
investigation of radio-protective mechanisms
existing in animals and discovery of drugs which cause bone marrow recovery following
deadly irradiation. During this screening research one of the vertebrate animal species was
found to be extremely radio-resistant, about 100-fold more resistant than humans. Specific
molecules from that animal, which are responsible for stimulation of adult stem cells (stem
cells modulators) have been discovered, characterized and synthetically produced. These
molecules augment recovery of bone marrow and blood and, therefore, induce survival and
recovery of the whole organism after high doses of chemotherapy, irradiation and after age
related damages.
BMR Solutions revealed the importance and the clinical relevance of BMRH family of stem
cell modulators in thousands of animals in several disease and aging models. We created a
broad pipeline addressing various clinical needs. Our business model includes collaborations
surrounding particular drug candidates for development, strategic partnership and
commercialization.
Company Name: BMR Solutions
Contact Details
Address: 49 Sokolov st, Herzeliya, Israel
Phone: 972-54-5696682
Fax: 972-3-5492874
Email: [email protected]
Website: www.bmrsolutions.co.il
Exhibition Representatives
Name: Ronen Kahana
E-mail: [email protected]
Category: Biopharmaceutical Company
13 | P a g e
Company Profile:
BrainStorm (Nasdaq: BCLI) is a US/Israeli
biotechnology company developing NurOwn®,
innovative adult stem cell therapies for incurable
neurodegenerative diseases with unmet need,
such as Amyotrophic Lateral Sclerosis (ALS, also
known as Lou Gehrig's disease), Multiple Sclerosis
(MS), and Parkinson’s disease (PD). These
devastating diseases have limited treatment
options and as such, represent highly unmet
medical needs. The U.S. Food and Drug
Administration (FDA) and the European Medicines
Agency (EMA) granted Orphan Drug Designation
to NurOwn®, the company's autologous, adult
stem cell product candidate for the treatment of
ALS. Final results of BrainStorm’s Phase I/II and
Phase IIa clinical trials with the first ALS patients
treated with the company's NurOwn® therapy indicated that the therapy is safe, does not
cause any adverse side effects, and shows initial indications of significant efficacy.
BrainStorm is running an FDA approved multi-center double-blind placebo controlled Phase
II clinical trial for ALS in the US at three major medical centers: Mass. General and UMass
hospitals in Boston and at the Mayo Clinic in Rochester (MN).
Technology Description:
Bone marrow cells are harvested from the patient, and Mesenchymal Stromal stem cells
(MSC) are isolated and expanded in culture. Using the company's core cell differentiation
technology, the MSC are then induced to differentiate into MSC-NTF cells (Mesenchymal
Stromal Cells-secreting Neurotrophic Factor) and transplanted back into the patient at or
near the site of damage (the muscles and spinal cord for ALS; spinal cord for MS; the brain
for Parkinson’s disease). BrainStorm’s proprietary process for propagating Mesenchymal
Stem Cells (MSC), their differentiation into NeuroTrophic factor-(NTF) secreting cells (MSC-
NTF), and their transplantation at, or near, the site of damage, offers the hope of repairing
degenerated tissues and curing the underlying pathology, rather than simply treating its
symptoms.
BrainStorm's approach has a high safety profile based on its use of autologous, adult,
Mesenchymal cells, which are free of the risk of rejection, tumor formation, controversy or
ethical issues.
Company Name: Brainstorm Cell
Therapeutics
Contact Details
Address: 3 University Plaza Drive, Suite
320, Hackensack, NJ 076 01
Phone: 201-488-0460
Fax: 201-430-7555
Email: [email protected]
Website: www.brainstorm-cell.com
Exhibition Representative Name: Tony Fiorino, MD, PhD Chief Executive Officer E-mail: [email protected] Category: Biotechnology/Cell Therapy
14 | P a g e
Company Profile:
Brainsway Ltd. is dedicated to the development
and marketing of Deep TMS (Transcranial Magnetic
Stimulation) systems - novel, noninvasive medical
devices for treatment of a wide range of
neurological and psychopathological disorders. In
principle, any brain-related disorder that is
associated with pathological activity of specific
brain sites may be treated by this method.
Potential applications include addiction,
schizophrenia, obesity, eating disorders,
Parkinson's disease, Alzheimer's disease, autism
and post-traumatic stress disorder. FDA cleared
Brainsway’s treatment of major depression and is
performing 4 multi-center pivotal trials (FDA-IDE)
for OCD, BiPolar, Addiction and PTSD. The unique
technology of Brainsway is based on patents filed
by the U.S. National Institute of Health (NIH) and by the company. Brainsway has an exclusive
license from the NIH for the patent and technology. Headquartered in Jerusalem, Israel, the
company’s ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol
'BRIN'.
Technology Description:
Transcranial magnetic stimulation (TMS) is a noninvasive technique used to apply brief
magnetic pulses to the brain. The pulses are administered by passing high currents through an
electromagnetic coil placed adjacent to a patient's scalp. The pulses induce an electric field in
the underlying brain tissue. When the induced field is above a certain threshold, and is directed
in an appropriate orientation relative the brain's neuronal pathways, localized axonal
depolarizations are produced, thus activating the neurons in the relevant brain structure.
Standard TMS coils are limited to activation of only cortical brain regions, up to a depth of
about 1.5 cm.
The unique technology of Brainsway Deep TMS System enables direct non-invasive activation of
deep brain structures. Deep TMS is a breakthrough in the search for a non-invasive approach
for treating common brain disorders. Deep TMS uses a unique, patented coil design to produce
directed electromagnetic fields that can induce excitation or inhibition of neurons deep inside
the brain. The treatment is non-invasive, with no significant side effects, no systemic effect (in
contrast to drugs), and no need of hospitalization or anesthesia.
Company Name: Brainsway Ltd.
Contact Details
Address: 19 Hartom St. By-Net Building,
Jerusalem 91451 Israel
Phone: 972-2-5824030
Fax: 972-2-5812517
Email: [email protected]
Website: www.brainsway.com
Exhibition Representatives
Name: Ronen Segal, COO
E-mail: [email protected]
Contact Person
Name: Ronen Segal, COO
E-mail: [email protected]
15 | P a g e
Company Profile:
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an
advanced clinical stage drug development
company with a platform technology that
addresses multi-billion dollar markets in the
treatment of cancer, inflammatory disease, and
sexual dysfunction. The Company’s CF101 is in
Phase II/III trials for the treatment of psoriasis,
with data expected in Q1 2015. Following a
successful Phase II trial for rheumatoid arthritis,
the Phase III study design was recently
completed. Can-Fite’s liver cancer drug CF102 is in
Phase II trials and the first patient was dosed in
Q4 2014. Enrollment is expected to be completed
by Q4 2015. CF102 has been granted Orphan Drug
Designation by the U.S. Food and Drug
Administration and is approved for Compassionate Use by Israel’s Ministry of Health. Can-
Fite’s newest drug candidate, CF602 has shown efficacy in the treatment of erectile
dysfunction in preclinical studies. The Company’s drug candidates have an excellent safety
profile with experience in over 1,200 patients in clinical studies to date. Can-Fite’s
intellectual property portfolio consists of 150 patents issued and pending.
Technology Description:
The platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a
target and a biological marker. The company’s pipeline of drugs are synthetic, highly specific
agonists and allosteric modulators targeting A33AR. All drugs are orally bioavailable with an
excellent safety profile. Can-Fite’s intellectual property includes 14 patent families including
74 international patents, protecting the composition of matter, synthesis of matter, and
clinical applications. The company has 50 publications in peer reviewed scientific journals.
Company Name:
CANFITE BioPharma Ltd.
Contact Details
Address: 10 Bareket Street,
Kiryat Matalon, P.O.Box 7537
Petach Tikva 49170, Israel
Phone: +972-3-924 1114
Fax: +972-3-924 9378
Email: [email protected]
Website: www.canfite.com
Exhibition Representatives
Name: Dr. Sari Fishman, Ph.D.
E-mail: [email protected]
16 | P a g e
Company Profile:
Compugen (Nasdaq: CGEN) is a leading drug
discovery company focused on monoclonal
antibodies and therapeutic proteins in the fields
of immunology and oncology, with a specific focus
on immuno-oncology.
The Company utilizes a broad and continuously
growing integrated infrastructure of proprietary
scientific understandings and predictive platforms,
algorithms, machine learning systems and other
computational biology capabilities for
the predictive discovery of novel drug target
candidates, which are then advanced in its
Pipeline Program. The discovery and development
of monoclonal antibody (mAb) therapeutic
candidates against selected Compugen-discovered
novel drug targets is performed at Compugen's
wholly-owned US subsidiary located in South San
Francisco.
Compugen is working on several exciting programs focused on its novel immune checkpoint
target candidates including CGEN-15049, CGEN-15052 & CGEN-15027, shown to affect key
components of the immune system known to be involved in anti-tumor immune responses,
supporting their potential as a promising targets for cancer immunotherapy. Compugen
plans to advance multiple programs for cancer immunotherapy in parallel, including one or
more to be advanced by Compugen into future clinical trials.
During 2013, Compugen initiated its second focused discovery program of novel candidates
for antibody drug conjugate (ADC) cancer therapy. To date, we have discovered 5 novel ADC
target candidates, two of which have demonstrated positive initial experimental results.
Compugen's business model includes collaborations covering the further development and
commercialization of selected pipeline product candidates at various stages of development
and various forms of research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or other forms of revenue
sharing.
Company Name: Compugen Ltd.
Contact Details
Address: 72 Pinchas Rosen St.,
Tel-Aviv, Israel
Phone: +972-3-7658-585
Fax: +972-2 3-7658-555
Email: [email protected]
Website: www.cgen.com
Exhibition Representatives
Name: Tsipi Keren-Lehrer
E-mail: [email protected]
Contact Person
Name: Tsipi Keren-Lehrer
E-mail: [email protected]
Category: Drug Discovery
17 | P a g e
Company Name
DALI Medical Devices Ltd.
Contact Details
Address: 6 Nahal Harif St.
P.O. Box 13223
Yavne 8122503, Israel
Phone: +972-8-3730080
Fax: +972-8-8585857
E-mail: [email protected]
Website: www.dalimed.com
Exhibition Representative
Name: David Daily, CEO & Co-Founder
E-mail: [email protected]
Categories
Medical Devices, Drug Delivery Devices
Company Profile:
DALI Medical Devices (DALI) was founded in
2003 by a team with more than 15 years of
experience in developing innovative drug
delivery devices for the pharmaceutical industry.
DALI has developed a family of innovative
autoinjectors (in collaboration with Elcam
Medical) to improve patient compliance and
contribute to treatment success. Some of these
autoinjectors have received FDA clearance and
are part of Elcam’s offering to major pharma
companies. Leveraging its expertise, DALI is
developing a proprietary new line of safe, easy
autoinjectors: Innovative Safe Auto-Needles
(SANs) address unmet needs we identified in the
growing injectable drug-delivery arena.
DALI seeks pharmaceutical, biotech, financial, or
other strategic partners to bring our unique SANs to
market.
Technology Description:
The proprietary SAN product family has been designed with a hidden needle, automatic
needle insertion, and safe automatic needle shielding after use for improved patient
compliance and adherence to treatment. The unique SANs can be customized for use with
all types of syringes. They have an extremely simple user interface and cost-effective design.
All SANs reduce needle phobia, anxiety and pain perception by hiding the needle, ensuring
consistent needle penetration depth and angle, preventing needlestick injuries, and allowing
for user-controlled injection speed for increased comfort.
The SANs family includes:
SAN: Intended for use with any type of luer syringe
SAN-DV: Intended for use in combination with drugs in vials
SAN-P: Intended for use with staked-needle prefilled syringes
18 | P a g e
Company Profile:
Foamix Pharmaceuticals is a clinical-stage
specialty pharma company, focused on
developing and commercializing of proprietary
topical foams for the treatment of acne and
other skin conditions. Foamix's lead product
candidates currently in clinical stage:
Minocycline Foam
FMX101 Minocycline foam for moderate-
to-severe acne.
FMX102 Minocycline foam for impetigo
FMX103 Minocycline foam for Rosacea
Doxycycline Foam
FDX104 Doxycycline foam for chemotherapy-induced rash
Partnerships: Foamix collaborates with leading pharmaceutical companies to create
advanced products with superior convenience, compliance and efficacy.
Intellectual property: To date Foamix has 79 issued patents worldwide, of which 37 are in
the U.S.
Technology Description:
Foamix Pharmaceuticals has nine different foam-based platforms that enable us to
formulate and stabilize a wide variety of drugs and deliver them directly to their target site.
The company’s products are mainly directed for the treatment of dermatological disorders,
and in certain cases Woman's health and GI conditions. Our development capabilities range
from formulation development to scale-up, GMP manufacturing, preclinical and clinical
studies.
Advantageous topical treatment: Foams offer an innovative and more convenient means of
topical treatment of the skin. This advantage of Foamix’s foam leads to improved
compliance and better efficacy.
Company Name:
Foamix Pharmaceuticals
Contact Details
Address: 2 Holzman st., Rehovot, Israel
Phone: +972-8-9316233
Fax: +972-8-9474356
Email: [email protected]
Website: www.foamixpharma.com
Exhibition Representatives
Dr. Dov Tamarkin
Category: Pharmaceutical
19 | P a g e
Company Profile:
Immune Pharmaceuticals Inc. applies a
personalized approach to treatment, developing
novel, highly-targeted antibody therapeutics to
improve the lives of patients with inflammatory
diseases and cancer.
Technology Description:
The company’s lead product candidate,
bertilimumab, is in clinical development for
moderate to severe ulcerative colitis and Crohn’s
disease as well as bullous pemphigoid, an
orphan auto-immune dermatological condition.
Immune licensed worldwide rights for systemic
indications of bertilimumab from iCo
Therapeutics (TSX: ICO; OTCQX: ICOTF) in June
2011, while iCo retained rights to all ophthalmic
indications.
iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006
from MedImmune, the Global Research and Development Arm of AstraZeneca. Immune’s
pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted
delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for
Phase III. AmiKet has received Orphan Drug Designation for Post Herpetic Neuralgia.
Company Name: Immune Pharmaceuticals Inc.
Contact Details
Address: 430 East 29th Street, Suite 940
New York, NY 10016
Phone: 646-937-1941
Website: www.immunepharmaceuticals.com
Exhibition Representatives
Name: Dr. Daniel Teper
E-mail: [email protected]
Category: Biotech
20 | P a g e
Company Profile:
Immune System Key Ltd. was founded in 2005 by
Prof. Uziel Sandler and Dr. Yoram Devary. ISK is a
privately held company, engaged with discovery
and development of innovative treatments to
malignant and autoimmune diseases with strong
unmet needs. Its assets are based on novel human
secreted peptides, which were discovered by the
founders.
ISK’s lead compound is Nerofe. Nerofe was
granted by the FDA with orphan drug status for
AML treatment. ISK has finished phase 1 dose
escalation stage with Nerofe with great success.
We have discovered novel MOA through which
Nerofe act against tumors in human body. The
company is now in preparation to phase IIa. ISK
Ltd is heavily supported by the Israeli Chief
Scientist; the company was granted by 4
consecutive grants from the Israeli Chief Scientist for a total sum of 2.5M$.
Technology Description:
ISK Ltd has finished phase 1 clinical trial with Nerofe in cancer patients with progressive
disease. Nerofe is highly safe in humans-no toxic effects were seen during the trial. Nerofe is
stable in human blood.
All anti-cancer drugs act against one specific biological process that supports cancer
progression: some drugs specifically induce inhibition of tumor cells proliferation by direct
induction of death of cancer cells, others specifically induce immune response against cancer
cells or only anti-angiogenic effect to inhibit creation of blood vessels around cancer cells.
Nerofe is the first highly safe anti-cancer agent that inhibits all 3 biological processes that
support cancer progression mentioned above. In phase 1 we saw very strongly:
1. Induction of strong anti-angiogenic effect.
2. Activation of anti-cancer immune response
3. Nerofe has direct strong inhibitory effect on cancer cell proliferation.
We have developed a novel marker that its presence in patient’s biopsy can predict success
of treatment with Nerofe. Positive marker patients stayed in the trial for 6 month or longer.
Company Name: Immune System Key
Contact Details Address: 318/7 Rosenblatt St., Jerusalem 97460, Israel Phone: +972 50 2597032 Fax: +972 2 6751179 Email: [email protected] Website: www.immuneSK.com Exhibition Representatives Name: Dr. Yoram Devary E-mail: [email protected] Contact Person Name: Dr. Yoram Devary E-mail: [email protected]
Category: Bio Pharma
21 | P a g e
Company Profile:
KAHR Medical is an Israeli biotech startup
company pioneering the development of ‘Dual
Signaling Proteins’ (DSP); fusion proteins with
two functional ends. KAHR has two active drug
development programs; KAHR-102 (CTLA4-FasL),
the company’s lead product that is expected to
initiate Phase-I/II in lymphoma patients during
2015, and KAHR-101 (Fn14-TRAIL) that has
completed Proof-Of-Concept in solid tumor and
autoimmune disease models and is ready for
process scale-up and toxicology. In addition,
KAHR has secured IP protecting hundreds of new
DSP combinations that are predicted to form
DSP higher-structures such as homo-hexamers
and clusters, which are based on TNF-
superfamily ligands and receptors. KAHR seeks
partners for the development of its large DSP drug portfolio.
Technology Description:
‘Dual Signaling Proteins’ (DSP) are multifunctional proteins that are formed by fusing the
extracellular domain of a Type-I membrane protein to the extracellular domain of a Type-II
membrane protein, forming one protein with two functional sides. This novel molecular
structure allows the facilitation of a unique mode-of-action that cannot be achieved by
simply administering the DSP protein elements as separate units. Multiple DSP molecules
have been intensely studied during the past decade and their promise as drug candidates
was documented in many scientific publications.
Like other multifunctional proteins, DSPs exhibits strong synergistic effects by affecting
multiple biological pathways in parallel. Moreover, KAHR has identified the importance of
higher-order structures, namely homo-hexamers and functional clusters, on the superior
activities of DSP molecules and has formed strong IP to protect hundreds if these molecules.
Company Name: KAHR Medical
Contact Details
Address: POB-1200, Hadassah Medical
Center, Jerusalem 91120
Phone: 97246292112
Fax: 972737962160
Email: [email protected]
Website: www.kahr-medical.com
Exhibition Representatives
Name: Dr. Noam Shani
E-mail: [email protected]
Category: Biotechnology
22 | P a g e
Company Profile:
NovellusDx is dedicated to delivering the
actionable intelligence that oncologists require
to choose the right therapy for each patient.
NovellusDx provides comprehensive functional
gene profiling of individual patient tumors
including charting the full landscape of known
and unknown mutations that drive cancer
progression and their response to targeted
drugs.
In addition, NovellusDx’s Precision Cancer
Analysis System™ (PCAS™) helps biopharma
companies identify subgroups of cancer patients
who are likely to respond to existing therapies,
stratify patients to enable more efficient trials
and isolate new mutations to target.
Achievements to Date:
• Dozens of case studies showing added value to NGS
• More than 150 FFT’s tumor samples from around the world
• IVD product core technology POC
Technology Description:
Overview of the process:
1) A small amount of the tumor biopsy is taken from the patient and sent to the
NovellusDx lab.
2) Personalized chips containing the patient oncogenes are printed. The genes are
expressed in live cells.
3) The chips are scanned through an automated high content microscopy system and the
oncogenic activity level associated with each specific gene is determined.
4) The information is presented as a map of the signaling pathways superimposed with all
relevant clinical information.
NovellusDx reports the signaling pathway activity due to the mutations in the patient’s
genes and their response to a battery of drugs.
Company Name: NovellusDx
Contact Details
Address: Jerusalem Bio-Park. Hadassah
Medical Center Campus, Jerusalem
Phone: +972(02)5001100
Fax: +972(02)5477099
Email: [email protected]
Website: www.novellusdx.com
Exhibition Representatives
Name: Dr. Yoram Altschuler
E-mail: [email protected]
Category: Personalized Medicine
23 | P a g e
Company Profile:
Oramed Pharmaceuticals (NASDAQ: ORMP)
has developed an innovative technology to
transform injectable treatments into oral
therapies.
Oramed’s flagship product, an oral insulin
capsule, has the potential to better the lives
of millions of diabetics around the world –
allowing, amongst other things, type 2
patients to begin insulin therapy earlier
without fear of needles.
Oramed’s oral insulin is currently in
advanced clinical trials under the US FDA for
both type 1 and type 2 diabetes.
In addition to oral insulin, the company’s
proprietary POD™ (Protein Oral Delivery) technology can be used to orally administer a
number of protein-based therapies, which are available only via injection.
Technology Description:
Oramed’s POD™ technology has been designed to protect orally delivered proteins from
detrimental enzymatic activity within the gastrointestinal tract and to enhance their
absorption across the intestinal wall.
The active protein is protected within a capsule that features a highly protective coating as
well as specialized protease inhibitors.
Drug availability is further secured by an absorption enhancer that facilitates protein passing
across the intestinal barrier.
Company Name:
Oramed Pharmaceuticals
Contact Details
Address: Hi-Tech Park 2/4 Givat Ram
Jerusalem
Phone: 972-2-566-0001
Fax: 972-2-566-0004
Email: [email protected]
Website: www.oramed.com
Exhibition Representatives
Name: Nadav Kidron
E-mail: : [email protected]
Category: Pharmaceutical
24 | P a g e
Company Profile:
Raziel Therapeutics is a clinical-stage
pharmaceutical company developing a
proprietary drug (NCE) that after a single
injection into subcutaneous fat, converts
white adipose tissue (WAT) into thermogenic,
brown-like adipose tissue (BAT).
Raziel has finalized all pre-clinical studies
according the FDA guidelines. The company
had a successful Pre IND meeting with the FDA
during January 2014.
Raziel’s prime-candidate, RZL-012, is a first-in-
class, injectable drug to treat obesity.
Raziel accomplished the production and
formulation of RZL-012 under cGMP conditions, and will be ready for first-in-human clinical
trial at Q2 2015.
Technology Description:
We are getting fat because we do not burn enough calories of the consumed food.
Thermogenesis in large animals is different than that of small rodents and Raziel carefully
verified that its drug acts in small and large mammals as well. Raziel’s novel drug is able to
convert energy-storing white-adipose-tissue (WAT) into energy-burning brown-like adipose
tissue (BAT), as evident by the histological, cellular and molecular studies. Moreover, the
physiological outcome of this tissue-remodelling is an outstanding local thermogenesis as
clearly demonstrated in human-size pigs. This thermogenesis lasts for several months
following a single treatment, with the ensuing ~30-50% reduction in s.c. fat at the treated
site. The molecular target of Raziel proprietary drug was also identified and is part of Raziel
IP.
Company Name: Raziel Therapeutics Ltd
Contact Details
Address: Hadassah Ein Kerem Jerusalem
Phone: 972 2 6250907
Fax: 972 2 6250901
Email:[email protected]
Website: Raziel-therapy.com
Exhibition Representatives
Name: Alon Bloomenfeld
E-mail: [email protected]
Category: Pharmaceutical
25 | P a g e
Company Profile:
PolyPid is a clinical stage specialty
pharmaceutical company focused on the
clinical and commercial development products
based on our proprietary PLEX™ (Polymer-Lipid
Encapsulation MatriX) platform in the field of
extended release, local drug delivery where
current local or systemic administration has
limited effect, is too toxic, or both. PolyPid’s
lead product, BonyPid-1000™, is a PLEX based
product that coats bone graft substitute with
antibiotics and intended for filling bone voids
or defects while supporting an antibacterial
protected bone healing process. BonyPid-1000
contains a broad-spectrum antibiotic,
doxycycline hyclate, to reduce microbial
colonization on the bone void filler. BonyPid-
1000 has completed a pilot clinical trial in severe open fractures indication, demonstrating
excellent safety and efficacy results, including 0% infections in the target fracture and 0%
amputations after 6-12 months follow up (vs. average of 25% and 14% respectively in
historical control group and known literature).
PolyPid is looking for partners to the following research programs: (a) Anti-Inflammatory - a
localized and controlled delivery of a very small, yet effective dexamethasone dose with
minimal systemic side effects, demonstrated safety and efficacy in a small animal model; (b)
Anti-Cancer - reducing the overall dose of toxic chemotherapeutic agents for a prolonged,
local medication while achieving effectiveness that is at least comparable to systemic
administration; (c) Growth factors – created an effective, controlled release of proteins using
several types of growth factors, such as BMP-2 with excellent bone growth in rat calvarium
bone defects.
Technology Description:
The PLEXTM platform is a matrix made of thousands of alternating layers of polymers and
lipids that entrap a therapeutic drug that enables an effective prolong localized drug delivery
in the body. Many drugs can be used, including small molecules, peptides, proteins and
nucleic acids Protected drug reservoir - protection from in vivo hydration and enzymatic
degradation Prolonged duration - Days >>Weeks >> Months, pre-programmed as needed
Constant and controlled release rate, pre-programmed as needed Versatile solutions –
multiple drug combinations can be used No chemical bonds are formed between the drug
and the formulation compounds Administration – pure structures as well as coating of
medical devices
Company Name: PolyPid
Contact Details
Address: 18 Hasivim st., Petach-Tikva,
Israel
Phone: +972-747195700
Fax: +972-747195718
Email: [email protected]
Website: www.polypid.com
Exhibition Representatives
Name: Amir Weisberg, Noam Emanuel
E-mail: [email protected]
Contact Person
Name: Asaf Bar
E-mail: [email protected]
26 | P a g e
Company Profile:
Sheltagen Medical Ltd was founded in 2009
by Orit Rosenberg PhD in order to develop
and promote a method of human bone
generation in laboratory conditions. The
company develops human bone tissue for
implantation in patients with fractures in
their bones or instability in spine. The
product is tailored for a specific patient
because it uses his own bone cells and blood
components. This product is individualized
for a patient and therefore shouldn’t be
rejected by the patients’ organism. Presently
our product is in the introductory state. We
plan to establish the most efficient and safe method for generating bone in laboratory that
should be customized for implantation for a specific patient. Critical factors in our business
are to get the approval from regulatory authorities (FDA, EU etc) for production. Our team
consists of Orit Rosenberg PhD, who is a founder of the company and holds all its ownership,
and who is an expert in bone cells culturing, and Nahum Rosenberg MD, who is CEO of the
company. Dr Nahum Rosenberg is a specialist in Orthopaedic surgery and experienced in the
basic research in bone biology.
Technology Description:
Our method for bone production in laboratory is unique because it involves several
components, which never have been combined before, i.e. self-human bone cells seeded on
inorganic matrix, cultured in media containing self-blood serum and exposed to mechanical
stimulation by vibration in a narrow range of optimal frequency and displacement
parameters of the movement. We showed in laboratory studies that the generated in vitro
tissue has all the characteristics of vital live bone tissue. Additionally we showed in in vitro
and in animal studies that the material is safe, i.e. has no cytotoxic and no carcinogenic
effects. We also showed that the generated in vitro bone material is effective to heal and
close “critical gaps” in bone in animal model. According to the previous verification there is
no similar method published or patented elsewhere. The patents have been already issued
in Europe and Israel.
We seek an initial investment which will enable us to construct the production facility, to
accomplish the process of the optimal production of bone tissue in vitro, to determine the
regulatory strategy for the product, including the safety requirements, and to be able to
perform phase 0/1 clinical study.
Company Name: Sheltagen Medical Ltd
Contact Details:
Address: Yefe Nof 22A, Atlit
3030000,Israel
Phone: +972 54 4685130
Fax: +972 4 8590930
Email: [email protected]
Website:www.sheltagen.com
Exhibition Representatives
Name: Nahum Rosenberg MD
E-mail: : [email protected]
27 | P a g e
Company Profile:
Vascular Biogenics Ltd., operating as VBL
Therapeutics (NASDAQ:VBLT), is a late- stage
clinical biopharmaceutical company focused
on the discovery, development and
commercialization of first-in-class
treatments for cancer. VBL has also
developed a proprietary platform of small
molecules, Lecinoxoids, for the treatment of
chronic immune-related indications. The
Company's lead oncology product candidate,
VB-111, is a gene-therapy based biologic
agent for solid tumor indications, that is
initially being developed for recurrent
glioblastoma, or rGBM, an aggressive form of
brain cancer. Phase 2 interim data show
statistically-significant benefit in overall survival for VB-111 in rGBM, providing proof-of-
concept, with good safety and tolerability. VB-111 has received orphan drug designation in
both the United States and Europe. In addition, VB-111 was granted Fast Track designation
by the FDA for prolongation of survival in patients with glioblastoma that has recurred
following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to
begin the pivotal Phase 3 trial for VB-111 in rGBM in mid-2015, under a special protocol
assessment agreement (SPA) granted by the FDA.
Technology Description:
VBL’s innovative, proprietary Vascular Targeting System (VTS™) platform technology enables
systemic administration of gene therapy to either destroy or promote angiogenic blood
vessels. VTS is both tissue- and condition-specific, allowing for targeted and limited gene
expression in endothelial cells. The VTS platform technology comprises three components: a
viral vector, a promoter and a transgene. Once the gene therapy has reached the angiogenic
blood vessels, the PPE-1-3X promoter activates expression of the transgene to produce a
desired protein in the endothelial cells of those vessels. For oncology applications, the
transgene selected is designed to destroy angiogenic blood vessels that feed solid tumors.
For other potential applications, such as the treatment of ischemia, a different transgene
can be selected that is designed to promote the development of angiogenic blood vessels.
Company Name: VBL Therapeutics
Contact Details
Address: 6 Yonathan Netanyahu St.
Or Yehuda, 60376 Israel
Phone: 972-3-6346450
Fax: 972-3-6346449
Email: [email protected]
Website: www.vblrx.com
NASDAQ: VBLT
Exhibition Representatives
Name: Dr. Eyal Breitbart, PhD
E-mail: [email protected]
Category: Biopharmaceutical
28 | P a g e
Company Profile:
XTL is an Israeli biotech company that is
developing two products, both with
optimistic/compelling clinical data: (1)
hCDR1, a novel compound working via a
unique mechanism of action, for the
treatment of Systemic Lupus Erythematous
(SLE), which has undergone 2 Phase 1 and a
Phase 2 trial involving more than 400
patients; and (2) the rights to use
erythropoietin for the treatment of end
stage multiple myeloma patients.
Technology Description:
hCDR1 ameliorates the lupus-related
autoimmune process by specific upstream
immunomodulation through the generation
of regulatory T cells, initiating a cascade of events which resume immune balance. hCDR1’s
beneficial effects in SLE were demonstrated in >200 animal experiments, which results have
been published in >40 peer-reviewed articles. hCDR1 has been studied in 2 placebo
controlled Phase I trials and a placebo controlled Phase II trial. The 3 studies consisted of
over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a
favorable safety profile. The Phase 2 trial did not meet its primary efficacy endpoint (SLEDAI
scale); however, the trial showed encouraging results in its secondary clinical endpoint, the
BILAG index. The FDA has since directed that the primary endpoint in future trials for Lupus
therapies, including those for hCDR1, should be based on either the BILAG index or the SLE
Responder Index.
Recombinant Human Erythropoietin (“rHuEPO”), a known agent for anemia, is being
developed to prolong the survival of patients with advanced Multiple Myeloma (“MM”). Our
rHuEPO for treatment of multiple myeloma was granted orphan drug designation from the
FDA. A clinical observation confirmed the high success rate of rHuEPO in treating patients
with MM. Six patients, whose expected survival was less than 6 months, continued
treatment with rHuEPO beyond the initial designed 12 week period, and lived for 38–94
months with rHuEPO (with a good quality of life). This clinical observation was further
supported by pre-clinical animal studies and extensive lab work.
Company Name:
XTL Biopharmaceuticals Ltd.
Contact Details
Address: 85 Medinat Hayehudim St.,
Herzliya Pituach
Phone: +972-9-9557080
Fax: +972-9-9519727
Email: [email protected]
Website: www.xtlbio.com
Exhibition Representatives
Name: Josh Levine
E-mail: [email protected]
Category: Biotech
29 | P a g e
NOTES
30 | P a g e
31 | P a g e
